Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Wonjun, Son"'
Autor:
Eunjung Lee, Hyejin Chung, Yangsoon Lee, Young Bong Park, Eun-Jung Lee, Hyunmo Koo, Mikyeong Ju, Ju Young Park, Sujin Ahn, Junhwan Kim, Kyeongsu Park, Wonjun Son, Jaehyun Eom, Hanbyul Lee, Jaeho Jung, Jonghwa Won, Se-Woong Oh
Publikováno v:
Regular and Young Investigator Award Abstracts.
Publikováno v:
Biophys J
The totally asymmetric simple exclusion process (TASEP), which describes the stochastic dynamics of interacting particles on a lattice, has been actively studied over the past several decades and applied to model important biological transport proces
Autor:
Yangsoon Lee, Kyeong-Su Park, Wonjun Son, Sora Kim, Hyunseong Youn, Jiseon Yoo, Hanbyul Lee, Jonghwa Won
Publikováno v:
Cancer Research. 83:2941-2941
ROR1, a member of the ROR (Receptor Tyrosine Kinase-Like Orphan Receptor)-family, is overexpressed in the process of embryo and fetal development, and controls cell polarity, cell migration and neurite growth. The expression is gradually reduced as d
Autor:
Eunjung Lee, Hyejin Chung, Yangsoon Lee, Eun-jung Lee, Young Bong Park, Ju Young Park, Sujin Ahn, Junhwan Kim, Kyoung Kyu Ahn, Kyeongsu Park, Wonjun Son, Donghoon Yeom, Jaeho Jung, Jonghwa Won, Se-Woong Oh
Publikováno v:
Cancer Research. 82:1139-1139
Although HER2-targeted therapies such as Herceptin® (trastuzumab) have dramatically improved outcomes for solid cancer patients with HER2 overexpression, it remains a challenge to cure the HER2 positive cancer patients with resistance to current HER
Autor:
Seung-Woo Lee, Shinai Lee, Wonjun Son, Eunyoung Park, Yunji Park, Park Kyeongsu, Sora Kim, Ji-Hae Kim, Yeon-Woo Kang, Yangsoon Lee, Jonghwa Won, Han Wook Park, Yong-Gyu Son, Jung Uijung, Young-Min Kim, Dain Moon, Gihoon You, Hyekang Kim, Eom Jaehyun, Chung Hyejin, Jaeho Jung
Publikováno v:
Science Advances. 7
Cancer immunotherapy with 4-1BB agonists has limited further clinical development because of dose-limiting toxicity. Here, we developed a bispecific antibody (bsAb; B7-H3×4-1BB), targeting human B7-H3 (hB7-H3) and mouse or human 4-1BB, to restrict t
Autor:
Gihoon, You, Yangsoon, Lee, Yeon-Woo, Kang, Han Wook, Park, Kyeongsu, Park, Hyekang, Kim, Young-Min, Kim, Sora, Kim, Ji-Hae, Kim, Dain, Moon, Hyejin, Chung, Wonjun, Son, Ui-Jung, Jung, Eunyoung, Park, Shinai, Lee, Yong-Gyu, Son, Jaehyun, Eom, Jonghwa, Won, Yunji, Park, Jaeho, Jung, Seung-Woo, Lee
Publikováno v:
Science Advances
Tumor-targeted T cell costimulatory antibody augments antitumor immunity by enhancing tumor-killing T cells within the tumor.
Cancer immunotherapy with 4-1BB agonists has limited further clinical development because of dose-limiting toxicity. He
Cancer immunotherapy with 4-1BB agonists has limited further clinical development because of dose-limiting toxicity. He
Autor:
Dae Won Kim, Sung Byungje, Yangsoon Lee, KyeongBae Kim, Su Jin Ahn, Wonjun Son, Yeom Donghoon, J.K. Lee, Chung Hyejin, Weon-Kyoo You, Ju Young Park, Eun Jung Kim, Young Bong Park, Song Daehae, Mikyeong Ju, Eom Jaehyun, Ahn Jinhyung, Jaeho Jung, Moo Young Song, Jung Uijung, Jong Gyun Kim, Jun Hwan Kim, Eunjung Lee, Park Kyeongsu, Se-Woong Oh, Min Hyeok Jee, Kyoung Kyu Ahn, Byung Hyun Choi
Publikováno v:
Cancer Research. 80:6524-6524
4-1BB (TNFSF9, CD137) is a member of the tumor necrosis factor receptor superfamily that functions as a potent costimulator to immune cells, especially T-cell. Although current 4-1BB-targeted strong agonistic antibody exhibit a considerable anti-tumo
Autor:
Gihoon You1, Yangsoon Lee2, Yeon-Woo Kang1, Han Wook Park1, Kyeongsu Park2, Hyekang Kim1, Young-Min Kim1, Sora Kim1, Ji-Hae Kim3, Dain Moon1, Hyejin Chung2, Wonjun Son2, Ui-jung Jung2, Eunyoung Park2, Shinai Lee2, Yong-Gyu Son2, Jaehyun Eom2, Jonghwa Won2, Yunji Park1, Jaeho Jung2 jaeho.jung@ablbio.com
Publikováno v:
Science Advances. 1/13/2021, Vol. 7 Issue 3, p1-15. 15p.